Fig. 4From: A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthmaTime to achieve 12% reversal (response) in FEV1 following S1226 or the placebo (P = 0.272)Back to article page